- Home
- NMS vs MIRA Comparison
NMS vs MIRA Comparison
Compare NMS & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | MIRA |
|---|---|---|
| Founded | 1993 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 61.1M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NMS | MIRA |
|---|---|---|
| Price | $11.80 | $1.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.0K | ★ 125.5K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.21 | $0.73 |
| 52 Week High | $12.18 | $2.45 |
Technical Indicators
Market Signals| Indicator | NMS | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 44.75 |
| Support Level | $11.67 | $1.38 |
| Resistance Level | $11.90 | $1.48 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 45.85 | 34.37 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.